Eko announces that it has become a new corporate partner of the National Association of Emergency Medical Technicians (NAEMT).

Peer-reviewed publication in the Journal of the American Heart Association found the AI algorithm detects clinically significant murmurs comparable to expert cardiologists

Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

App to Help Medical Students and Healthcare Providers Strengthen their Stethoscope Skills and Auscultation Knowledge

Eko wants every patient with chronic cardiovascular disease to be one click away from their doctor.

Bringing together science, technology, and comprehensive solutions to redefine what’s possible in healthcare.

Eko recognized for achievements in AI-powered analysis of cardiopulmonary disease.

Development of integrated AI digital health solutions to help patients better manage their cardiovascular health.

NIH Awards Eko $2.7M for clinical study on valvular heart disease detection.

Eko appoints new commercial leader.

The First AI-Powered telehealth platform for virtual pulmonary and cardiac exams.

During COVID-19, FDA Issues Emergency Use Authorization for algorithm designed to improve detection of heart failure.

Eko Named to the 2020 CB Insights AI 100.

Former FDA Medical Officer joins Eko as Chief Medical Officer.

Eko’s algorithms alert clinicians to the presence of heart murmurs and atrial fibrillation (AFib) during the physical exam.

FDA Grants ‘Breakthrough’ designation to Eko’s Low Ejection Fraction screening algorithm.

Eko and Mayo Clinic use ECG stethoscope DUO to effectively detect heart failure.

Eko closes $20M in Series B led by ARTIS Ventures.

Eko announced as finalist for UCSF Digital Health Awards.

Eko Collaborates with Mayo Clinic on a machine learning-based algorithm.

Eko closes $5M Series A led by ARTIS Ventures.